NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology drug development company, announced today the successful completion of the first stage...
REHOVOT, Israel, Nov. 9, 2021 /PRNewswire/ -- NeoTX Therapeutics, Ltd. (NeoTX), a clinical-stage immuno-oncology company, today announced a presentation on the company's lead program, naptumomab estafenatox (NAP), at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting being held November 10-14, 2021 at the Walter E. Washington convention Center, Washington D.C. The poster presentation will highlight preclinical data demonstrating that NAP enhances CAR-T cells potency and can boost CAR-T efficacy against solid tumors.
REHOVOT, Israel, Oct. 20, 2021 /PRNewswire/ -- NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology company, announced today that the first patient has been enrolled in the company's phase 2a clinical trial of naptumomab estafenatox (NAP), its lead Tumor Targeted Superantigen (TTS) candidate, in combination with docetaxel in patients with advanced non-small cell lung cancer (NSCLC).
REHOVOT, Israel, July 07, 2021 (GLOBE NEWSWIRE) -- NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology company, announced today that it will host a key opinion leader (KOL) webinar on overcoming checkpoint inhibitor resistance on Wednesday, July 14, 2021 at 10am Eastern Time.
NeoTX Therapeutics, a clinical-stage immuno-oncology company, announced that it received clearance from the US Food and Drug Administration (FDA) for the company’s Investigational New Drug (IND) application for naptumomab estafenatox (NAP)